Sodium Fusidate Oral: A Bacterial Protein Synthesis Inhibitor by Preventing the Turnover Ofelongation Factor G (EF-G) from the Ribosome – Global Emerging Insight and Market Forecast 2021-2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Sodium Fusidate Oral – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

“SODIUM FUSIDATE ORAL – Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Prosthetic Joint Infection in 7 Major Markets. A detailed picture of the SODIUM FUSIDATE ORAL in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview

Sodium Fusidate oral, (also known as Fusidic acid, FA or sodium fusidate) acts as a bacterial protein synthesis inhibitor by preventing the turnover ofelongation factor G (EF-G) from the ribosome. Fusidic acid is effective primarily ongram-positive bacteria such as Staphylococcus species.

The drug is licensed for use as its sodium salt sodium fusidate, and it is approved for use under prescription in South Korea, Japan, UK, Canada, Europe, Australia, New Zealand, Thailand, India and Taiwan. A different oral dosing regimen, based on the compound’s Pharmacokinetic/pharmacodynamic (PK-PD) profile is in clinical development in the U.S. as Taksta.

SODIUM FUSIDATE ORAL Analytical Perspective

In-depth SODIUM FUSIDATE ORAL Market Assessment

This report provides a detailed market assessment of SODIUM FUSIDATE ORAL in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

SODIUM FUSIDATE ORAL Clinical Assessment

The report provides the clinical trials information of SODIUM FUSIDATE ORAL covering trial interventions, trial conditions, trial status, start and completion dates.

Scope of the Report

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug research and development activity details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around SODIUM FUSIDATE ORAL.
• The report contains forecasted sales for SODIUM FUSIDATE ORAL till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) for Prosthetic Joint Infection.
• The report also features the SWOT analysis with analyst insights and key findings of SODIUM FUSIDATE ORAL.

Report Highlights

• In the coming years, the market scenario for Prosthetic Joint Infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence SODIUM FUSIDATE ORAL dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other emerging products for Prosthetic Joint Infection are giving market competition to SODIUM FUSIDATE ORAL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of SODIUM FUSIDATE ORAL.
• This in-depth analysis of the forecasted sales data of SODIUM FUSIDATE ORAL from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the SODIUM FUSIDATE ORAL.

Key Questions Answered

• Which company is developing SODIUM FUSIDATE ORAL along with the phase of the clinical study?
• What is the technology utilized in the development of SODIUM FUSIDATE ORAL?
• What is the product type, route of administration and mechanism of action of SODIUM FUSIDATE ORAL?
• What is the clinical trial status of the study and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SODIUM FUSIDATE ORAL development?
• What are the key designations that have been granted to SODIUM FUSIDATE ORAL?
• What is the forecasted market scenario of SODIUM FUSIDATE ORAL?
• What is the history of SODIUM FUSIDATE ORAL and what is its future?
• What is the forecasted sales of SODIUM FUSIDATE ORAL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how these are giving competition to SODIUM FUSIDATE ORAL?
• Which are the late-stage emerging therapies under development for the treatment of the PPD?

Key Topics Covered:

1. Drug Overview

1.1. Product Detail

1.2. Mechanism of Action

1.3. Dosage and Administration

1.4. Research and development activity

1.4.1. Clinical Development

1.4.2. Safety and Efficacy

1.5. Other Development Activities

2. Market Assessment

2.1. 7MM Market Analysis

2.2. The United States Market

2.3. Germany Market

2.4. France Market

2.5. Italy Market

2.6. Spain Market

2.7. United Kingdom Market

2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/kpitb1

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900